Objective Obstructive sleep apnoea (OSA) is a risk factor for vascular disease and other adverse outcomes. These associations may be at least partly due to early endothelin-1 (ET-1)-mediated endothelial dysfunction (ED). Therefore, we assessed the relationships between subclinical sleep apnoea and plasma levels of ET-1.
Methods We performed a population-based study among 1255 young and healthy adults aged 25–41 years. Cardiovascular disease, diabetes or a body mass index >35 kg/m2 were exclusion criteria. Plasma levels of ET-1 were measured using a high-sensitivity, single-molecule counting technology. The relationships between subclinical sleep apnoea (OSA indices: respiratory event index (REI), oxygen desaturation index (ODI), mean night-time blood oxygen saturation (SpO2)) and ET-1 levels were assessed by multivariable linear regression analysis.
Results Median age of the cohort was 35 years. Median ET-1 levels were 2.9 (IQR 2.4–3.6) and 2.5 pg/mL (IQR 2.1–3.0) among patients with (n=105; 8%) and without subclinical sleep apnoea (REI 5–14), respectively. After multivariable adjustment, subclinical sleep apnoea remained significantly associated with plasma levels of ET-1 (β=0.13 (95% CI 0.06 to 0.20) p=0.0002 for a REI 5–14; β=0.10 (95% CI 0.03 to 0.16) p=0.003 for an ODI≥5). Every 1% decrease in mean night-time SpO2 increased ET-1 levels by 0.1 pg/mL, an association that remained significant after multivariable adjustment (β=0.02 (95% CI 0.003 to 0.033) p=0.02).
Conclusions In this study of young and healthy adults, we found that participants with subclinical sleep apnoea had elevated plasma ET-1 levels, an association that was due to night-time hypoxaemia. Our results suggest that ED may already be an important consequence of subclinical sleep apnoea.
- SLEEP APNEA
- Received August 21, 2016.
- Revision received October 27, 2016.
- Accepted December 4, 2016.
- Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
What is already known about this subject?
Prior research has demonstrated a tight relationship of sleep apnoea with hypertension and other cardiovascular events among patients with clinical sleep apnoea syndrome.
What does this study add?
This is the largest population-based study among young and healthy adults investigating the relationship of subclinical sleep apnoea and plasma endothelin-1 (ET-1) levels. This study demonstrates that apnoea-induced hypoxaemia is significantly related to increased ET-1 levels, suggesting that endothelial dysfunction may be an important consequence of obstructive sleep apnoea already at a subclinical stage.
How might this impact on clinical practice?
This association is independent of other important cardiovascular risk factors (eg, smoking, body mass index, blood pressure, renal function, high-sensitivity C reactive protein, glycated haemoglobin, low-density lipoprotein, high-density lipoprotein) and supports the importance of even subclinical sleep apnoea in the development of cardiovascular disease.
Obstructive sleep apnoea (OSA) is a highly prevalent disorder, often underdiagnosed and significantly associated with adverse outcomes, including hypertension,1–5 stroke,6 coronary artery disease7 ,8 and sudden death.9 ,10
Although the precise pathophysiology linking OSA with vascular disease remains to be delineated, endothelial dysfunction (ED) may play a central role in this association.11 ,12 ED is characterised by reduced vasodilatation and enhanced vasoconstriction, as well as by increased prothrombotic and inflammatory activity.13 In this context, endothelin-1 (ET-1) has been implicated as an important factor in the development of vascular dysfunction and cardiovascular disease,14–17 suggesting that ET-1 may be an easily measurable surrogate for endothelial function. ET-1 is released by endothelial cells and increases vascular tone by acting on underlying smooth muscle cells in a paracrine manner.
The resulting imbalance between vasodilator and vasoconstrictor endothelial mediators with overproduction of ET-1 increases vascular permeability and decreases antithrombotic activity, thereby promoting the occurrence of vascular disease.18 ,19 ED is therefore considered an early state of atherosclerosis and cardiovascular disease20 and may constitute a potential link that relates OSA with adverse cardiovascular outcomes. Preliminary evidence from animal models of sleep apnoea and data from patients with OSA support this hypothesis, but data from large-scale population-based studies are currently unavailable.21 In addition, it remains unclear whether impaired vascular function is an early manifestation of OSA, or whether it may be a consequence of OSA-related comorbidities such as hypertension or obesity. Finally, quantification of endothelial function has been difficult and time-consuming, particularly in large-scale population-based studies. The emergence of new ET-1 assays facilitates its measurement and enables easier ET-1 quantification in large populations.22
To address some of these issues, we assessed the relationships between subclinical sleep apnoea (respiratory event index (REI)=5–14, oxygen desaturation index (ODI) ≥5, mean night-time blood oxygen saturation (SpO2), and per cent of sleeping time with SpO2<90%) and plasma levels of ET-1 in a large cohort of young and healthy adults.
The genetic and phenotypic determinants of blood pressure (BP) and other cardiovascular risk factors (GAPP) study is an ongoing prospective population-based cohort study in the Principality of Liechtenstein. Details about study design and methods have been described previously.23 Briefly, between May 2010 and December 2013, all inhabitants of the Principality of Liechtenstein aged 25–41 years were invited to participate in GAPP. Exclusion criteria were a body mass index (BMI) >35 kg/m2, prevalent cardiovascular disease, known and treated sleep apnoea syndrome, renal failure, current intake of antidiabetic drugs or any other severe illnesses.
Of the 2170 included participants, 1415 (65%) participants underwent night-time pulse oximetry with nasal flow measurement. To investigate effects of subclinical sleep apnoea, participants with a REI≥15 per hour (n=25) were excluded to minimise confounding due to potentially undiagnosed OSA syndrome. Further, we excluded 135 participants due to missing or incomplete sleep study parameters (n=57), missing ambulatory BP recordings (n=57) or other missing covariates (n=21), such that 1255 participants remained for the current analyses. Written informed consent was obtained from each participant. The local ethics committee approved the study protocol.
Night-time pulse oximetry
Night-time pulse oximetry with nasal flow measurement was performed using the validated ApneaLink (ResMed, San Diego, California, USA) device24 ,25 to obtain information on night-time oxygen saturation, apnoeas and hypopnoeas. Sleep study analyses were based on automatic scoring analysis. The sleep study was performed at the patient's home. Individuals were instructed by a trained study nurse on how to put on the nasal cannula and the oximetry probe. An apnoea was defined as a reduction of nasal airflow of ≥80% compared with baseline for ≥10 s. Hypopnoea was defined as a reduction of nasal airflow of ≥30% compared with baseline followed by a simultaneous decrease in oxygen saturation ≥4%. The apnoea index was defined as the number of apnoeas per hour. The REI was defined as the number of apnoeas and hypopnoeas per hour of sleep according to the 2015 updated version of the American Academy of Sleep Medicine (AASM) criteria.26–28 Subclinical sleep apnoea was defined to be present when the REI was 5, but <15 per hour. The ODI was defined as the number of oxygen desaturations ≥4% per hour of sleep.29 An ODI of ≥5 per hour was considered to be abnormal. In addition to REI and ODI, mean night-time SpO2 and the per cent of total sleep time with SpO2<90% were calculated.
The 24 hours BP measurements were obtained using a validated device (BR-102 plus, Schiller AG, Switzerland). Trained study nurses handled the devices which were programmed to obtain BP measurements every 15 min during daytime and every 30 min during night-time. If participants had <80% of valid measurements, the BP study was repeated whenever possible. BP measurements were only included in the analysis if ≥25 daytime and ≥8 night-time measurements were available. Daytime and night-time periods were individually defined through a 24-hour diary completed by each participant. Daytime hypertension was defined as mean systolic BP≥135 mm Hg and/or mean diastolic BP≥85 mm Hg,30 respectively. Night-time hypertension was defined as mean systolic BP≥120 mm Hg and/or diastolic BP≥70 mm Hg, respectively.30 Individuals currently taking antihypertensive medication were considered to be hypertensive.
Fasting venous blood samples were obtained from each participant and immediately centrifuged. Blood aliquots were immediately stored at −80°C. A research-use high-sensitive, single-molecule counting assay (Erenna Immunoassay System, Singulex, Alameda, California, USA) was used to measure ET-1 from frozen EDTA plasma samples.22 The ET-1 assay’s limits of blank and quantification were 0.07 and 0.33 pg/mL, respectively. Interassay coefficients of variation were 7% at an ET-1 concentration of 1.2 pg/mL and 6% at an ET-1 concentration of 1.8 pg/mL.
Plasma levels of glucose, creatinine, high-sensitive C reactive protein (hs-CRP), insulin, triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol were analysed on a Roche Cobas 6000 analyser (F. Hoffmann La Roche, Switzerland) using fresh blood samples.23 Glycated haemoglobin (HbA1c) was analysed using high-performance liquid chromatography (Bio-Rad D-10, Bio-Rad Laboratories AG, Switzerland).23 Pre-diabetes was defined as HbA1c between 5.7% and 6.4%. For the estimation of the glomerular filtration rate (eGFR), we used the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.23
Assessment of other study variables
Questionnaires were used to obtain information about personal, medical, lifestyle and nutritional factors. Smoking status was self-assessed using three categories: current, past and never. BMI was calculated as body weight in kilogram divided by height in metres squared.
Distributions of continuous variables were evaluated using skewness, kurtosis and inspection of the histogram. Continuous variables were presented as medians (IQRs) and compared with the Wilcoxon rank sum test. Categorical variables were compared using χ2 tests. Owing to its distribution, ET-1 was used as a log-transformed variable in all analyses. Multivariable linear regression analyses were constructed using ET-1 as the outcome variable. Separate models were used to evaluate different sleep apnoea parameters, including REI, ODI, mean night-time SpO2 and per cent of sleeping time with a SpO2<90%. Age, sex and BMI adjusted models were further adjusted for a predefined set of covariates, including smoking status, HDL cholesterol, LDL cholesterol, TG, eGFR, HbA1c, mean systolic and diastolic ambulatory BP and hs-CRP.
Subgroup analyses were performed for age, sex, BMI, eGFR, hs-CRP, pre-diabetes, TG, smoking status, and daytime and/or night-time hypertension. Differences across subgroups were assessed by including multiplicative interaction terms in the non-stratified models. All analyses were performed using SAS V.9.4 (SAS Institute, Cary, North Carolina, USA). A p value <0.05 was used to indicate statistical significance.
Baseline characteristics stratified by the presence or absence of subclinical sleep apnoea are presented in table 1. Of 1255 participants, 590 (47%) were male. Subclinical sleep apnoea was found among 105 (8%) participants according to a REI score between 5 and 14, 85 (81%) men and 20 (19%) women (p<0.0001). Median ET-1 levels were 2.9 pg/mL (IQR 2.4–3.6) and 2.5 pg/mL (IQR 2.1–3.0) among patients with and without subclinical sleep apnoea (p<0.0001), respectively. Patients with subclinical sleep apnoea were significantly older (37 (IQR 33–39) vs 35 years (IQR 30–39) p=0.02), and had a higher BMI (27 vs 24 kg/m2, p<0.0001) and higher hs-CRP levels (1.4 (IQR 0.6–3.2) vs 0.9 mg/L (IQR 0.5–1.9) p=0.0007). They also had higher 24-hour ambulatory systolic (128 (IQR 119–136) vs 122 mm Hg (IQR 114–130) p<0.0001) and diastolic (81 (IQR 76–86) vs 77 mm Hg (IQR 72–82) p<0.0001) BP levels, a higher prevalence of current smokers (30% vs 21%, p=0.01), and lower HDL (1.3 (IQR 1.1–1.5) vs 1.5 mmol/l (IQR 1.3–1.8) p<0.0001) and higher LDL levels (3.2 (IQR 2.6–3.9) vs 2.8 mmol/L (IQR 2.3–3.5) p<0.0001), as shown in table 1.
Results of sleep study
The results of the sleep study according to subclinical sleep apnoea are presented in table 2. All sleep apnoea indices were significantly different between both groups. Patients with subclinical sleep apnoea had a lower breathing rate, whereas sleep duration and mean heart rate were not different.
Subclinical sleep apnoea and plasma ET-1 levels
Linear regression models on the relationship between OSA indices and ET-1 levels are shown in table 3. In unadjusted models, subclinical sleep apnoea was significantly associated with log-transformed ET-1 (β=0.17 (95% CI 0.10 to 0.24) p<0.0001 for a REI 5–14). Multivariable adjustment slightly attenuated this relationship, but subclinical sleep apnoea remained strongly associated with ET-1 levels (β=0.13 (95% CI 0.06 to 0.20) p=0.0002 for a REI 5–14). A similar robust association was found between ET-1 levels and an elevated ODI, present in 124 participants (multivariable-adjusted β=0.10 (95% CI 0.03 to 0.16) p=0.003). Every 1% decrease in mean night-time SpO2 resulted in an increase in the plasma concentration of ET-1 of 0.1 pg/mL, as shown in figure 1. This association remained significant after multivariable adjustment (β=0.02 (95% CI 0.003 to 0.033) p=0.02) (table 3). In addition, the per cent of sleeping time with SpO2<90% was also associated with plasma levels of ET-1 (multivariable-adjusted β=0.012 (95% CI 0.002 to 0.023) p=0.02). Figure 2 summarises the effect sizes of the different sleep apnoea indices on log-transformed plasma levels of ET-1.
Subgroup analyses are presented in table 4. We found a borderline significant sex by REI interaction (p value 0.049), suggesting that the association between subclinical sleep apnoea and ET-1 may be somewhat stronger among women (β=0.27 (95% CI 0.12 to 0.43) p=0.0005 for a REI 5–14). No evidence for effect modification was found for the other parameters investigated, including age, BMI, pre-diabetes, smoking status, hypertension, eGFR, hs-CRP and TG.
To the best of our knowledge, this is the first large population-based study investigating the relationship between subclinical sleep apnoea and plasma levels of ET-1 among young and healthy adults. In our analysis, we found a strong and independent relationship between several OSA indices and plasma levels of ET-1 that was mainly mediated by hypoxaemia subsequent to apnoeas and hypopnoeas. All parameters related to intermittent or continuous hypoxaemia were significantly associated with ET-1 levels, including mean night-time SpO2, per cent of sleeping time with SpO2<90%, ODI≥5 and REI 5–14. According to these findings, our data suggest that ED might already be present in subclinical sleep apnoea and that it may be directly caused by hypoxaemia. It is important to re-emphasize that confounding effects of undiagnosed OSA were minimised by excluding all participants with REI≥15.
If we assume that ET-1 is a direct marker of ED,17 ,31 ,32 then taking into account competing risk factors for ED such as hypertension, diabetes and obesity is of utmost importance, because of the multifactorial and complex genesis of vascular dysfunction. It is therefore important to emphasise that our results remained highly significant after comprehensive multivariable adjustment. It is also noteworthy that our results were obtained in a cohort of young and healthy adults with very low plasma ET-1 levels and a low burden of comorbidities. Our findings suggest that even subclinical forms of OSA may impair endothelial function. In this context, our findings are in accordance with prior basic experimental studies showing that intermittent hypoxaemia impairs endothelial function33–35 and increases the production of ET-1 in cultured human endothelial cells14 as well as in vivo among untreated patients with severe OSA.36 Kato et al37 showed an impairment of resistance-vessel endothelium-dependent vasodilation among eight middle-aged patients with OSA compared with nine control patients underscoring the relationship between OSA and hypertension. Finally, the magnitude of the association between subclinical sleep apnoea and ET-1 should also be stressed. We previously showed that in this cohort, elevated ET-1 levels were strongly related to currently smoking cigarettes.38 The β coefficients for subclinical sleep apnoea exceeded those for smoking, underscoring the potential importance of subclinical sleep apnoea in the pathogenesis of cardiovascular disease.
Sex-specific analyses suggested that the relationship between subclinical sleep apnoea and ET-1 levels seems to be stronger among women. While the p value of interaction was of borderline significance, there are recent studies also reporting sex-specific differences in the relationship between OSA and plasma levels of cardiac troponin T.39 This study showed a significant association between a diagnosis of OSA and plasma levels of troponin T among middle-aged women but not men.39 These findings may suggest that the effect of OSA may be particularly deleterious among women, but further studies are needed to confirm this hypothesis.
The major strengths of this study include its population-based design and the large number of well-characterised young and healthy participants undergoing night-time pulse oximetry with nasal airflow measurement. In this population, exposure to environmental confounders is relatively short and individuals with pre-existing cardiovascular comorbidities were excluded. There are also some potential limitations that should be taken into consideration for the interpretation of our results. First, the cross-sectional design does not allow us to draw causal inferences or to assess the directionality of the observed effects. However, it is very unlikely that increased ET-1 levels induce night-time hypoxaemia, such that the latter seems to be the driving force for elevated ET-1 levels.40 Second, the generalisability of our results to other populations is uncertain. Third, we did not use polysomnography as the gold standard diagnostic tool for sleep apnoea. However, it has been shown that combining pulse oximetry with nasal flow measurement has a high sensitivity and specificity for detecting patients with sleep apnoea.24 ,25 Finally, we did not directly measure endothelial function in our population. However, previous studies showed a good correlation between plasma ET-1 levels and endothelial function.18
In conclusion, this study of young and healthy adults provides strong evidence of an independent relationship between subclinical sleep apnoea and plasma levels of ET-1. Our results further suggest that the increased ET-1 levels might be directly related to apnoea-induced hypoxaemia and that this phenomenon is already present in young and healthy individuals at a subclinical stage. These findings are independent of other important cardiovascular risk factors (eg, smoking, BMI, BP, renal function) and may, at least in part, explain the tight relationship of clinical sleep apnoea syndrome with hypertension and other adverse cardiovascular events.
- Received August 21, 2016.
- Revision received October 27, 2016.
- Accepted December 4, 2016.
Contributors TS and DC were involved in all parts of the conduct of this study: design of the study (TS, DC), acquisition of data (TS, DC), analysis and/or interpretation (TS, DC), drafting of the manuscript (TS), revising the manuscript (TS, DC). All other authors were involved in the conduct of this study and approved the revised version of the manuscript.
Funding The Liechtenstein Government, the Swiss Heart Foundation, the Swiss Society of Hypertension, the University of Basel, the University Hospital Basel, the Hanela Foundation, Schiller AG and Novartis supported the GAPP study. DC was supported by a grant of the Swiss National Science Foundation (PP00P3_133681 and PP00P3_159322). Endothelin-1 was measured free of charge by Singulex, Alameda, CA 94502, USA. The ApneaLink devices were provided by ResMed Schweiz AG (Basel, Switzerland).
Competing interests JT and JE are employees of Singulex and hold stock options in Singulex. They are also co-inventors on patents filed in regard to assay methods for measuring endothelin-1 levels.
Patient consent Obtained.
Ethics approval The local ethics committee approved the study protocol.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.